secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2024-11-19T23:59:59+00:00
Accession:  0000950170-24-128686
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa Therapeutics enters at-the-market equity facility for up to $100M
------------------------------------------------------------------------

- Agreement with Jefferies LLC dated Nov 19, 2024 to sell up to $100M of common stock at-the-market.
- Commission to Jefferies is up to 3.0% of gross proceeds; company reimburses certain expenses.
- Proceeds intended for clinical development, working capital, and general corporate purposes.
- No obligation to sell any shares; company may suspend or terminate the agreement at any time.
- Shares registered under effective S-3 filed May 13, 2024; prospectus supplement filed Nov 19, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000095017024128686/0000950170-24-128686-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000095017024128686/atos-20241119.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-128686

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer